Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study

Soon-Ki KIM; Ki-Young YOO; Kun-Soo LEE; Taiju HWANG; Yong-Mook CHOI; Eun-Jin CHOI; Sang-Kyu PARK.
Journal of Korean Medical Science ; : e5-2018.
Artículo en Inglés | WPRIM | ID: wpr-764849

Documentos relacionados

  1. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
  2. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
  3. Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study.
  4. Recombinant porcine factor VIII in patients with congenital haemophilia A with inhibitors undergoing surgery: Phase 3, single-arm, open-label study.
  5. Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.
  6. rFVIII-Fc in severe haemophilia A: The incentive switch in case of high risk of joint bleedings.
  7. Efficacy and safety of turoctocog alfa in patients with hemophilia A requiring surgical procedures: A multicentre retrospective study.
  8. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
  9. Unresolved hemostasis issues in haemophilia.
  10. Real-world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non-interventional, post-authorization safety study.